Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.9486
Abstract: Key Points Question Are sperm-associated antigen 5 (SPAG5) transcript or protein expressions associated with treatment response in patients with estrogen receptor–positive breast cancer? Findings In this cohort study including 12 720 patients with estrogen receptor–positive breast… read more here.
Keywords: receptor positive; positive breast; spag5; breast cancer ... See more keywords
The antiviral drug telaprevir induces cell death by reducing FOXA1 expression in estrogen receptor α (ERα)‐positive breast cancer cells
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13303
Abstract: Previously, we found that telaprevir (Tel), the inhibitor of hepatitis C virus NS3/4A serine protease, reduces estrogen receptor α (ERα) content at the transcriptional level without binding to the receptor, prevents ERα transcriptional activity, and… read more here.
Keywords: cell death; estrogen receptor; breast cancer; induces cell ... See more keywords
Codon adaptation by synonymous mutations impacts the functional properties of the estrogen receptor-alpha protein in breast cancer cells.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13399
Abstract: Estrogen receptor-alpha (ERα) positivity is intimately associated with the development of hormone-dependent breast cancers. A major challenge in the treatment of these cancers is to understand and overcome the mechanisms of endocrine resistance. Recently, two… read more here.
Keywords: estrogen receptor; codon adaptation; receptor alpha; functional properties ... See more keywords
Development of heterodimeric estrogen receptor alpha antagonists to target simultaneously the ligand and coactivator binding site.
Sign Up to like & getrecommendations! Published in 2023 at "Archiv der Pharmazie"
DOI: 10.1002/ardp.202200638
Abstract: One-third of breast cancer patients will develop recurrent cancer within 15 years of endocrine treatment. Notably, tumor growth in a hormone-refractory state still relies on the interaction between estrogen receptor alpha (ERα) and upregulated coactivators.… read more here.
Keywords: binding site; site; estrogen receptor; coactivator binding ... See more keywords
Estrogen receptor α revised: Expression, structure, function, and stability
Sign Up to like & getrecommendations! Published in 2022 at "BioEssays"
DOI: 10.1002/bies.202200148
Abstract: Estrogen receptor α (ERα) is a ligand‐dependent transcription factor that regulates the expression of estrogen‐responsive genes. Approximately 70% of patients with breast cancer are ERα positive. Estrogen stimulates cancer cell proliferation and contributes to tumor… read more here.
Keywords: stability; breast cancer; estrogen receptor; expression ... See more keywords
An aptasensor for rapid and sensitive detection of estrogen receptor alpha in human breast cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Biotechnology and bioengineering"
DOI: 10.1002/bit.26819
Abstract: The analysis of estrogen receptor (ER) expression in breast carcinomas plays a crucial role in determining the endocrine responsiveness of tumors for systemic adjuvant therapy. Conventionally, the ER levels in breast carcinomas had been detected… read more here.
Keywords: human breast; detection; breast; aptasensor ... See more keywords
A multicenter phase II trial of neoadjuvant letrozole plus low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer (JBCRG‐07): therapeutic efficacy and clinical implications of circulating endothelial cells
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Medicine"
DOI: 10.1002/cam4.1516
Abstract: Neoadjuvant endocrine therapy has been reported to decrease tumor size, which leads to increased breast conservation rates. To improve the clinical response, metronomic chemotherapy with endocrine therapy is a promising strategy. A multicenter phase II… read more here.
Keywords: breast; receptor positive; positive breast; postmenopausal ... See more keywords
Estrogen receptor variant ER‐α36 facilitates estrogen signaling via EGFR in glioblastoma
Sign Up to like & getrecommendations! Published in 2022 at "Cell Biology International"
DOI: 10.1002/cbin.11877
Abstract: Glioblastoma (GBM) is a deadly and common primary brain tumor. Poor prognosis is linked to high proliferation and cell heterogeneity. Sex differences may play a role in patient outcome. Previous studies showed that ER‐α36, a… read more here.
Keywords: signaling via; estrogen receptor; estrogen; gbm ... See more keywords
De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34155
Abstract: The standard 5 years of endocrine therapy has demonstrated additional benefits compared with short‐term (2‐3 years) treatment in patients with estrogen receptor (ER)‐positive breast cancer; however, data specific to ER‐low positive breast cancer (1%‐10% by… read more here.
Keywords: estrogen receptor; breast cancer; patients estrogen; endocrine therapy ... See more keywords
Beyond the estrogen receptor: In search of predictive biomarkers for low‐grade serous ovarian cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34658
Abstract: Low ‐ grade ovarian cancer (LGOC) comprises a rare group of tumors, including serous, mucinous, and endometrioid subtypes, that collectively account for 10% of ovarian cancer (OC) deaths and are histologically and molecularly distinct from… read more here.
Keywords: estrogen receptor; grade serous; ovarian cancer; low grade ... See more keywords
Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low‐grade ovarian carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34661
Abstract: Advanced low‐grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However,… read more here.
Keywords: estrogen receptor; activity; low grade; grade ovarian ... See more keywords